Antiviral activity of topoisomerase II catalytic inhibitors against Epstein-Barr virus.
Antiviral activity of topoisomerase II catalytic inhibitors against Epstein-Barr virus.
复制标题
DOI：
10.1016/j.antiviral.2014.05.003
复制
发表时间：
2014-07
影响因子：
7.6
通讯作者：
Ting Wu;Yan Wang;Yan Yuan
中科院分区：
文献类型：
--
作者：
Ting Wu;Yan Wang;Yan Yuan
疱疹病毒需要几种细胞蛋白用于其裂解DNA复制，包括拓扑异构酶II（Topo II）。因此，Topo II可能是一种有效的抗疱疹病毒感染的药物靶标。在这项研究中，我们检查了几种Topo II催化抑制剂在阻断EB病毒复制和成为有效抗病毒药物方面的潜力。拓扑异构酶II催化抑制剂一般表现出显着的抑制EBV裂解复制和最小的细胞毒性。特别地，在本研究中测试的抑制剂中具有最佳选择性指数（SI > 63）的（+）-芸香苷有效抑制EBV DNA复制和病毒体产生，但对细胞增殖显示出很小的不利影响，这表明其有可能成为治疗与EBV感染相关的人类疾病的有效且安全的药物。
Herpesviruses require several cellular proteins for their lytic DNA replication including topoisomerase II (Topo II). Thus, Topo II could be an effective drug target against herpesviral infection. In this study, we examined several Topo II catalytic inhibitors for their potentials in blocking EBV replication and becoming efficacious antiviral agents. Topo II catalytic inhibitors in general exhibited marked inhibition of EBV lytic replication and minimal cytotoxicity. In particular, (+)-rutamarin, with the best selectivity index (SI > 63) among the inhibitors tested in this study, is effective in inhibiting EBV DNA replication and virion production but shows little adverse effect on cell proliferation, suggesting its potential to become an efficacious and safe drug for the treatment of human diseases associated with EBV infection.